Glyburide
K-ATP channel blocker / Second generation oral hypoglycemic agent. Acts via ATP-dependent K+ channel (Kir6, KATP) block1. Inhibits Kir6 currents in the pancreas, causing an increase in intracellular Ca2+ and insulin secretion. Also inhibits recombinant CFTR Cl- channels with an IC50 of 20 μM2. Cell permeable.
Biochemicals & reagents
10238-21-8
Glibenclamide
1) Brogden et al. (1979), Glipizide: a review of its pharmacological properties and therapeutic use; Drugs, 18 329 2) Sheppard and Welsh (1992), Effect of ATP-sensitive K+ channel regulators on cystic fibrose transmembrane conductance regulator chloride currents; J. Gen. Physiol., 100 573
RT
TARGET: Ion channel; Inflammasome -- PATHWAY: Potassium channel; Calcium signaling; Pyroptosis -- RESEARCH AREA: Neuroscience; Cell death -- DISEASE AREA: Diabetes; InflammationNeurodegeneration